PBR Nachrichten

 

The collaboration, which marks Cellares' first development project in Asia, will explore adapting GenomeFrontier's virus-free process to the Cell Shuttle system. It aims to assist GenomeFrontier's clinical activities The post Cellares and GenomeFrontier to assess automated GF-CART01 production appeared first on Pharmaceutical Business review....

The approval covers patients with OSAS who continue to experience EDS while receiving treatment for airway obstruction. It also applies to narcolepsy with and without cataplexy, a condition The post Viatris' Wakix receives Japanese approval to treat OSAS and narcolepsy appeared first on Pharmaceutical Business review....

The arrangement offers a new regional pathway for long-acting HIV prevention in all PAHO Member States through its Regional Revolving Funds. The collaboration enables 14 countries, including Argentina, The post Gilead and PAHO agree to expedite lenacapavir access for HIV prevention appeared first on Pharmaceutical Business review....

The companies intend to work together on several research programmes focused on QurCan's Target-Engineered Responsive Polymer (TERP) polymer-lipid nanoparticle (PLNP) delivery platform development. QurCan uses its TERP platform The post Eli Lilly and QurCan sign genetic medicine deal appeared first on Pharmaceutical Business review....

Under the proposed arrangement, Sanofi will receive a 26.4% equity stake in Cheplapharm. The partnership expands on a working relationship between the two companies, which began in 2014. The post Cheplapharm to take over 20 medicines and three sites from Sanofi appeared first on Pharmaceutical Business review....

The revised guidance is intended for adults whose ES-SCLC has progressed after treatment with platinum-based chemotherapy. It recommends a monitoring period ranging between six and eight hours in The post FDA reduces monitoring time for Amgen's Imdelltra infusions appeared first on Pharmaceutical Business review....

The agreement involves the use of Modalis' CRISPR-GNDM (Guide Nucleotide-Directed Modulation) technology in combination with Exegenesis Bio's engineered muscle-tropic adeno-associated virus (AAV) capsid, EMC181. EMC181 is designed for The post Exegenesis Bio and Modalis sign research deal for Duchenne therapy appeared first on Pharmaceutical Business review....

A ribbon-cutting ceremony to mark the opening is scheduled for 24 September, with company leadership, employees, partners and community leaders expected to attend. According to ABEC, the site The post ABEC to expand global manufacturing network with new Wilson facility appeared first on Pharmaceutical Business review....

The financing was raised in a Series A round led by RA Capital Management, with participation from Forbion, Canaan Partners and other investors. Porustobart is a second-generation, Fc-enhanced The post Solstice Oncology secures $225m to drive porustobart's development for cancer appeared first on Pharmaceutical Business review....

Insight Partners and Medical Excellence Capital led the round, with additional investment from Pfizer Ventures and M Ventures, the corporate venture capital arm of Merck KGaA, all joining The post TwoStep Therapeutics secures $62.5m funding to advance TS-104 appeared first on Pharmaceutical Business review....

The new facility expands the company's capabilities in inflammation, oncology and data science. Gilead currently employs 11,000 people in the US, with more than 7,400 based in California The post Gilead launches research facility in US for new medicine development appeared first on Pharmaceutical Business review....

RXRG001 is a circular ribonucleic acid (RNA) therapy encoding human aquaporin-1, a protein involved in fluid transport. The therapy is encapsulated within lipid nanoparticles and directly administered to The post FDA grants RMAT designation to RiboX's RXRG001 for xerostomia appeared first on Pharmaceutical Business review....

The Liverpool Accelerate Laboratory was developed with the LSTM-led iiCON: Infection Innovation Consortium and received funding from the Liverpool City Region Combined Authority. It is due to open The post LSTM opens $23m robotic AI lab for infection research appeared first on Pharmaceutical Business review....

The purchase adds an established hypertension brand to Novartis' cardiovascular range. Novartis India's board cleared the deal, after which the company signed an asset purchase agreement and trademark The post Novartis India acquires Pfizer brands for $132m appeared first on Pharmaceutical Business review....

This combo is approved for adults with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer. The clearance applies when an estrogen receptor 1 (ESR1) mutation is The post FDA approves AstraZeneca's Etcamah combo for advanced breast cancer appeared first on Pharmaceutical Business review....

The 72,300ft² site is said to be the largest single-site contract development and manufacturing organisation (CDMO) facility in North America for radiopharmaceutical development to date. It supports low-to-high The post AtomVie opens $160m radiopharmaceutical manufacturing facility in Ontario appeared first on Pharmaceutical Business review....

The funding was led by BVF Partners, with participation from new investors Deep Track Capital and Perceptive Advisors. Existing backers included Catalio Capital Management, Cooley, Eli Lilly and The post Superluminal Medicines secures $60m to advance rare obesity therapy appeared first on Pharmaceutical Business review....

The agreement gives Médunik Canada immediate responsibility for Diacomit's sales, marketing, and medical affairs activities throughout the country. It aims to leverage Médunik Canada's network and rare disease The post Médunik and Biocodex sign exclusive agreement for Diacomit in Canada appeared first on Pharmaceutical Business review....

The contract allows Qilu Pharmaceutical to use the antibody, which was developed through Biocytogen's RenNano platform, in its research and development (R&D) activities focused on neuroscience therapeutics. It The post Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule appeared first on Pharmaceutical Business review....

The deal allows Novartis to exercise multiple options for exclusive global rights to develop subcutaneous versions of several of its products employing the berahyaluronidase alfa enzyme, also known The post Novartis signs deal with Alteogen for drug delivery appeared first on Pharmaceutical Business review....